Categories
Change Password!
Reset Password!
Dupilumab improves disease control, reduces itch and nodular lesions, and enhances quality of life in refractory prurigo nodularis patients with minimal safety concerns.
A new observational study across 10 hospitals in China offered real-world evidence supporting the dupilumab's effectiveness and safety in patients suffering from moderate-to-severe refractory prurigo nodularis (PN, an uncommon neuroinflammatory dermatosis). The study included 73 PN-affected patients (33 female, 40 male; mean age 45.9 ± 21.5 years) who commenced dupilumab (monoclonal antibody targeting interleukin-4Rα), with a follow-up of at least 16 weeks.
Disease control and quality of life improvements were assessed via the peak pruritus numeric rating scale (PP-NRS), investigator global assessment (IGA) for PN, and the dermatology life quality index for adults or children (DLQI/CDLQI). Based on reported adverse events, safety was assessed. Findings revealed that 84.9% of patients attained a clinically meaningful reduction in pruritus (≥4-point drop in PP-NRS) by week 12. The proportion of patients achieving IGA 0/1 (clear or almost clear skin) escalated from 0% at baseline to 37.0% at week 12 and 46.6% at week 16.
Patient-reported quality of life depicted remarkable improvement, with DLQI/CDLQI scores dropping from 16.6 ± 6.8 at baseline to 7.2 ± 4.9 at week 12 and 6.4 ± 4.5 at week 16. Dupilumab demonstrated a favorable safety profile, with only 1 patient reporting dry eyes as an adverse event. No serious side effects were witnessed, reinforcing its tolerability in real-world use. These findings confirm that dupilumab not only reduces pruritus and nodular lesions but also markedly enhances the quality of life in PN patients outside clinical trial settings. The study underscores dupilumab’s role as a safe and effective intervention for refractory PN.
Allergy
Effectiveness and Safety of Dupilumab for Prurigo Nodularis in China: A Multicentric and Observational Study
Zuotao Zhao et al.
Comments (0)